VivoSeq
Other

Glabellar Lines

2

Pipeline Programs↗

3

Active Trials↗

8

Companies Involved↗

Glabellar Lines is an early-stage landscape with 2 programs across 8 companies. The most active players are Eli Lilly, AbbVie, Eirion Therapeutics Inc.. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

1 program

Phase 3AbbVie logo

AbbVie

2 programs

Phase 3E

Eirion Therapeutics Inc.

0 programs

PreclinicalH

Huons Biopharma

0 programs

PreclinicalIpsen logo

Ipsen

0 programs

PreclinicalR

Revance Therapeutics, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

Botox

AbbVie

Phase 2
No programs
Phase 31

AGN-151586

AbbVie

Approved
No programs

Analysis

Trial Status

24

clinical trials

Completed18 · 75%
Unknown status3 · 13%
Active, not recruiting2 · 8%
Recruiting1 · 4%

Clinical Trials

Trial Activity

24 trials

To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)
Recruiting·HHuons Biopharma·Phase 3·NCT06205797·312 enrolled
Depth of Botulinum Neurotoxin Injection for Treatment of Glabellar Lines
Active, not recruiting·HHenry Ford Health System·Phase 1·NCT05766683·20 enrolled
A Study to Evaluate AI-09 In Participants With Glabellar Lines
Active, not recruiting·EEirion Therapeutics Inc.·Phase 2·NCT07321834·68 enrolled
AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines
Completed·AbbVie logoAbbVie·Phase 2·NCT04096326·198 enrolled
MT10109L in the Treatment of Glabellar Lines
Completed·MMedy-Tox·Phase 3·NCT03795922·234 enrolled
A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines
Completed·AbbVie logoAbbVie·Phase 3·NCT05248893·986 enrolled
Jeuveau Treatment of Glabellar Lines Using OLD Versus COLD
Completed·CClinical Testing of Beverly Hills·Phase 1·NCT05129319·30 enrolled
Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin
Completed·GGalderma R&D·N/A·NCT05089357·250 enrolled
A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines
Completed·AbbVie logoAbbVie·Phase 3·NCT05248880·309 enrolled
Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines
Completed·EEvolus, Inc.·Phase 2·NCT02184988·352 enrolled
Dysport in the Treatment of Glabellar Lines in Chinese Subjects
Completed·Ipsen logoIpsen·Phase 3·NCT02450526·520 enrolled
Phase 2a Study of DaxibotulinumtoxinA-lanm for Injection in Dynamic Forehead Lines and Glabellar Lines
Completed·RRevance Therapeutics, Inc.·Phase 2·NCT06411002·27 enrolled
A Study Of BOTOX For The Treatment Of Glabellar Lines
Completed·GSK logoGSK·Phase 3·NCT00408785·256 enrolled
Evaluation Onset Time of DWP450-004 and Safety in Moderate-severe Glabellar Lines
Completed·Daewoong Pharmaceutical Co. LTD. logoDaewoong Pharmaceutical Co. LTD.·Phase 4·NCT02568150·45 enrolled
Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006
Completed·EEvolus, Inc.·Phase 2·NCT02428608·570 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)